{
  "docId": "019de071-e0d6-76fb-ba84-d69d61ac5ee5",
  "docSlug": "1773642d94b9dc79507cf930970e5456",
  "documentTitle": "Certara | Investor Day Presentation Deck | 91 slides",
  "authorId": "certara",
  "authorName": "Certara",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 49,
  "pageCount": 91,
  "prevPage": 48,
  "nextPage": 50,
  "slideType": "precedent_table",
  "function": "cite_precedent",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide cites an FDA label report from 2013 as a precedent for using PBPK modeling in regulatory decision-making.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-e0d6-76fb-ba84-d69d61ac5ee5/49",
  "deckHref": "/decks/019de071-e0d6-76fb-ba84-d69d61ac5ee5",
  "deckJsonHref": "/decks/019de071-e0d6-76fb-ba84-d69d61ac5ee5.json",
  "deckAnchorHref": "/decks/019de071-e0d6-76fb-ba84-d69d61ac5ee5#slide-49",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "quote",
      "text": "The simulations of PBPK model provided a dose optimization strategy for combined use of ibrutinib with specific CYP3A inhibitors or inducers.",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03a4821f-007c-4adb-8e3d-2af55dc7419a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.74,
        "x": 0.13,
        "y": 0.38
      },
      "kind": "table",
      "text": "Table showing CYP3A modulators, goals, interaction mechanisms, and Ibrutinib dosing recommendations.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6273323-7d20-4386-81e2-53e1f97fa180",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.88,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Ibrutinib model used to inform dose adjustments in label",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60a0c2d7-e9ac-45ea-91a0-aacf55596097",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "7bab6932-531c-42c4-a2e4-495ecd93458a",
      "evidence": "Citing FDA label report to validate the use of PBPK modeling.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}